Clinical Trials Browser

Phase 3 × Congenital Abnormalities × Methotrexate × Clear all

NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute